<div id="readability-page-1"><p>JPMorgan Chase &amp; Co. trimmed its position in  BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Free Report) by 49.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities &amp; Exchange Commission. The firm owned 48,812 shares of the company's stock after selling 47,002 shares during the period. JPMorgan Chase &amp; Co.'s holdings in BeOne Medicines were worth $16,630,000 at the end of the most recent reporting period.</p><div><p><span></span><span>Get <strong>BeOne Medicines</strong> alerts:</span></p></div><ul><li>4 Stocks With Huge Cash Holdings at Silicon Valley Bank</li></ul><p>Other institutional investors and hedge funds have also added to or reduced their stakes in the company. PNC Financial Services Group Inc. bought a new stake in shares of  BeOne Medicines during the 2nd quarter valued at $228,000.  Geode Capital Management LLC purchased a new position in shares of  BeOne Medicines in the 2nd quarter worth about $8,622,000.  Creative Planning bought a new position in  BeOne Medicines in the 2nd quarter worth about $1,448,000.  Cetera Investment Advisers bought a new position in  BeOne Medicines in the 2nd quarter worth about $455,000.  Finally, Legal &amp; General Group Plc purchased a new stake in  BeOne Medicines during the 2nd quarter valued at about $13,857,000. Hedge funds and other institutional investors own  48.55% of the company's stock. </p><h2>Insider Buying and Selling</h2><p>In related news, SVP Chan Henry Lee sold 341 shares of the company's stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $300.00, for a total transaction of $102,300.00. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 2,665 shares of company stock worth $902,792 in the last three months. 6.62% of the stock is currently owned by corporate insiders. </p><h2>Wall Street Analyst Weigh In</h2><p>Several research analysts have recently issued reports on the stock. Sanford C. Bernstein upgraded shares of BeOne Medicines from a &#34;hold&#34; rating to an &#34;outperform&#34; rating and set a $414.00 target price on the stock in a research note on Monday, January 12th. Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of BeOne Medicines in a research note on Wednesday, January 21st. Guggenheim lifted their target price on BeOne Medicines from $400.00 to $410.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, February 27th. Jefferies Financial Group cut BeOne Medicines from a &#34;buy&#34; rating to a &#34;hold&#34; rating and decreased their price target for the stock from $420.00 to $290.00 in a research note on Monday, March 16th. Finally, Barclays upped their price target on BeOne Medicines from $394.00 to $405.00 and gave the company an &#34;overweight&#34; rating in a report on Friday, February 27th. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one  has given a Sell rating to the company's stock. According to data from MarketBeat, the stock  has an average rating of &#34;Moderate Buy&#34; and an average price target of $389.18.</p><p><b>View Our Latest Report on BeOne Medicines</b></p><h2>BeOne Medicines Trading Up 2.8%</h2><p>Shares of ONC stock opened at $283.45 on Thursday. The company has a current ratio of 3.41, a quick ratio of 3.08 and a debt-to-equity ratio of 0.22. BeOne Medicines Ltd. - Sponsored ADR has a 12-month low of $196.45 and a 12-month high of $385.22. The stock has a market capitalization of $31.10 billion, a P/E ratio of 112.48 and a beta of 0.53. The firm's 50 day moving average is $326.25 and its 200 day moving average is $327.68. </p><p>BeOne Medicines (NASDAQ:ONC - Get Free Report) last announced its earnings results on Thursday, February 26th. The company reported $0.58 earnings per share for the quarter, missing analysts' consensus estimates of $1.60 by ($1.02). The company had revenue of $1.50 billion for the quarter, compared to analysts' expectations of $1.45 billion. BeOne Medicines had a net margin of 5.37% and a return on equity of 10.70%.  Research analysts expect that  BeOne Medicines Ltd. - Sponsored ADR will post -5.82 earnings per share for the current year. </p><h2>BeOne Medicines Profile</h2> (Free Report)<p>BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than BeOne Medicines</li></ul><p><strong>Want to see what other hedge funds are holding ONC?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T05D?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T05D"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in BeOne Medicines Right Now?</h2><p>Before you consider BeOne Medicines, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BeOne Medicines wasn't on the list.</p><p>While BeOne Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>JPMorgan Chase & Co. reduced its stake in BeOne Medicines Ltd. by 49.1% in Q3, selling 47,002 shares, leaving it with 48,812 shares valued at $16.63 million. Other institutional investors have also adjusted their positions. Analysts have mixed ratings on the stock, with a consensus of "Moderate Buy" and an average price target of $389.18. BeOne Medicines' stock opened at $283.45, with a market cap of $31.10 billion and a P/E ratio of 112.48. The company reported earnings of $0.58 per share, missing estimates, and expects a loss of $5.82 EPS for the current year.</p>

Market Beat

iShares Global Healthcare

VG Health

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

iShares US Pharma

SPDR S&P Biotech

Beigene

VanEck Biotech ETF

Defiance Daily Target 2X Long JPM ETF

JPMorgan Chase

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

JPMorgan Chase & Co. Sells 47,002 Shares of BeOne Medicines Ltd. - Sponsored ADR $ONC